Lung artery thromboembolism in young patient with severe Wegener's granulomatosis in absence of traditional thrombotic risk factors


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Frequency, risk factors and pathogenesis of thrombotic events in patients with systemic ANCA-associated necrotizing vasculitides are reviewed. Patient with severe Wegener’s granulomatosis, who developed pulmonary artery thromboembolism in absence of thrombotic risk factors, is presented. Interrelations of thromboembolic events and systemic inflammatory response in systemic vasculitides are discussed.

全文:

受限制的访问

参考

  1. Новиков П.И., Семенкова Е.Н., Моисеев С.В. Современная номенклатура системных васкулитов // Клиническая фармакология и терапия. - 2013. - № 1. - C. 70-74.
  2. Gadola S.D., Gross W.L. Vasculitis in 2011: The renaissance of granulomatous inflammation in AAV// Nat Rev Rheumatol. - 2012. - Vol. 8(2). - P. 74-76.
  3. Pagnoux C., Wolter N.E. Vasculitis of the upper airways. // Swiss Med Wkly. - 2012. - Vol. 142. - w13541.
  4. Seo P., Stone J.H. The antineutrophil cytoplasmic antibody-associated vasculitides//Am J Med. - 2004. - Vol. 117(1). - P. 39-50.
  5. Wolff S., Fauci A., Horn R. et al. Wegener's granulomatosis//Ann Intern Med. -1974. - Vol. 81. - P. 513-525.
  6. Клименко С.В., Кривошеев О. Клинические особенности современного гранулематоза Вегенера: варианты течения, прогноз // Врач. - 2005. -№ 12. - C. 39-41.
  7. Stone J.H., Merkel P.A., Spiera R. et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis // N Engl J Med. - 2010 Jul 15. - Vol. 363(3). - P. 221-232.
  8. Мухин Н.А., Новиков П.И., Моисеев С.В. и др. Эффективность и безопасность генно-инженерных биологических препаратов у пациентов с ревматоидным артритом и другими ревматическими заболеваниями: проспективное неконтролируемое исследование // Клиническая фармакология и терапия. - 2012. - № 5. - C. 25-32.
  9. Бекетова Т.В. Гранулематоз с полиангиитом, патогенетически ассоциированный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения // Научнопрактическая ревматология. - 2011. - № 6. - C. 19—28.
  10. Новиков П.И., Семенкова Е.Н., Кривошеев О. Опыт использования моноклональных антител к рецепторам CD20 В-лимфоцитов (ритуксимаба) у больных с поражением почек при гранулематозе Вегенера // Терапевтический архив. - 2011. - № 11. - C. 70-76.
  11. Nies J. Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis // Clin Exp Immunol. - 2011. - Vol. 164(Suppl 1). -P. 27-30.
  12. Allenbach Y., Seror R., Pagnoux C., Teixeira L., Guilpain P., Guillevin L., et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients // Annals of Rheumatic Diseases. - 2009. - Vol. 68(4). - P. 564-567.
  13. Lamprecht P., deGroot K., Schnabel A., Csernok E., Liedvogel B., Gross W.L. Anticardiolipin antibodies and antibodies to beta(2)-glycoprotein I in patients with Wegener’s granulomatosis // Rheumatology. - 2000. - Vol. 39. -P. 568-570.
  14. Sebastian J.K., Voetsch B., Stone J.H. et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener’s granulomatosis with and without history of a thrombotic event // J Rheumatol. - 2007. - Vol. 34. - P. 2446-2450.
  15. Merkel P.A., Chang Y., Pierangeli S.S., Convery K., Harris E.N., Polisson R.P. The prevalence and clinical association of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases//Am J Med. - 1996. - Vol. 101. - P. 576-583.
  16. Bagot C.N., Arya R. Virchow and his triad: a question of attribution // British Journal of Haematology. - 2008. - Vol. 143(2). - P. 180—190.
  17. Brotman D.J., Deitcher S.R., Lip G.Y., Matzdorff A.C. Virchow’s triad revisited // Southern Medical Journal. - 2004. - Vol. 97(2). - P. 213—214.
  18. Gaffo A.L. Thrombosis in vasculitis // Best Pract Res Clin Rheumatol. - 2013. - Vol. 27(1). - P. 57-67.
  19. Torbicki A., Perrier A., Konstantinides S. et al. Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) // Eur. Heart J. - 2008. - Vol. 29 (18). - P. 2276-2315.
  20. White R.H. The epidemiology of venous thromboembolism // Circulation. -2003. - Vol. 107(23 suppl 1). - P. 14-18.
  21. Heit J.A. Venous thromboembolism: disease burden, outcomes and risk factors // J Thromb Haemost. - 2005. - Vol. 3(8). - P. 1611-1617.
  22. Kearon C. Natural history of venous thromboembolism // Circulation. -2003. - Vol. 107(23 suppl 1). - P. 122-130.
  23. Kahn S.R. How 1 treat postthrombotic syndrome // Blood. - 2009. -Vol. 114. - P. 4624-4631.
  24. Pengo V, Lensing A.W., Prins M.H. et al: Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism // N Engl J Med. - 2004. -Vol. 350(22). - P. 2257-2264.
  25. Merkel P.A., Lo GH., Holbrook J.T., Tibbs A.K., Allen N.B., Davis Jr. J.C., et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study // Annals of Internal Medicine. - 2005. -Vol. 142(8). - P. 620-626.
  26. Weidner S., Hafezi-Rachti S., Rupprecht H.D. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis // Arthritis Rheum. - 2006. - Vol. 55. - P. 146-149.
  27. Stassen P.M., Derks R.P., Kallenberg C.G., Stegeman C.A. Venous thromboembolism in ANCA-associated vasculitis-incidence and risk factors // Rheumatology. - 2008. - Vol. 47(4). - P. 530-534.
  28. Hergesell O., Egbring R, Andrassy K. Presence of anticardiolipin antibodies discriminates between Wegener’s granulomatosis and microscopic polyarteritis. ANCA-Associated Vasculitides: Immunological and Clinical Aspects //Adv Exp Med Bio. - 1993. - Vol. 336. - P. 393-396.
  29. Von Scheven E., Lu T.T., Emery H.M., Elder M.E., Wara D.W. Thrombosis and pediatric Wegener’s granulomatosis: Acquired and genetic risk factors for hypercoagulability // Arthritis Rheum. - 2003. - Vol. 49. - P. 862-865.
  30. Hansen K.E., Moore K.D., Ortel T.L., Allen N.B. Antiphospholipid antibodies in patients with Wegener’s granulomatosis and polyarteritis nodosa // Arthritis Rheum. - 1999. - Vol. 42. - P. 2250-2252.
  31. Sebastian J.K., Voetsch B., Stone J.H. et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener’s granulomatosis with and without history of a thrombotic event // J Rheumatol. - 2007. - Vol. 34. - P. 2446-2450.
  32. Nies J. Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis// Clin Exp Immunol. - 2011. - Vol. 164(Suppl 1). - P. 27-30.
  33. Алекберова З.С., Герасимова Е.В., Голоева Р.Г., Насонов Е.Л. Тромбозы и ревматические заболевания: частота встречаемости и механизмы развития: обзор и собственные данные // Научно-практическая ревматология. - 2012. - Vol. 1. - С. 65-71.
  34. Козловская Н.Л., Шилов Е.М., Серикова С.Ю. Дисфункция эндотелия у больных системной красной волчанкой // Терапевтический архив. -2010. - Vol. 2. - С. 70-74.
  35. Springera J., Villa-Forte A. Thrombosis in vasculitis // Curr Opin Rheumatol. - 2013. - Vol. 25. - С. 19-25.
  36. Johannesdottir S.A., Horvath-Puho E., Dekkers O.M. et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study // JAMA 1ntern Med. - 2013. Apr 1. - Р. 1-10.
  37. Bautz D.J., Preston G.A., Lionaki S. et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis // J Am Soc Nephrol. - 2008. - Vol. 19. - Р. 2421-2429.
  38. Pendergraft W.F., Preston G.A., Shah R.R. et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3 // Nat Med. - 2004. - Vol. 10. - Р. 72-79.
  39. Maino A., Rossio R., Cugno M. et al. Hypereosinophilic Syndrome, Churg- Strauss Syndrome and parasitic diseases: possible Links between Eosinophilia and Thrombosis // Curr Vasc Pharmacol. - 2012. - Vol. 10. -Р. 670-675.
  40. Geerts W.H., Bergqvist D., Pineo G.F. et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines: 8th Edition // Chest. - 2008. - Vol. 133(6 Suppl). - P. 381S-453S.
  41. Cushman M. Treating Acute Venous Thromboembolism - Shift with Care // N Engl J Med. - 2013. - Vol. 369. - P. 865-866.
  42. Glynn R.J., Danielson E., Fonseca F.A. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism // N Engl J Med. - 2009. - Vol. 360. - P. 1851-1861.
  43. Rodriguez A.L., Wojcik B.M., Wrobleski S.K. et al. Statins, inflammation and deep vein thrombosis: a systematic review // J Thromb Thrombolysis. - 2012. - Vol. 33. - P. 371-382.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##